Bionano Genomics Inc (BNGO) Share Price

Is Bionano Genomics (BNGO) a Scam Company?

Bionano Genomics is a legitimate company that specializes in Optical Genome Mapping (OGM) technology. Their flagship product, the Saphyr system, is used to detect structural variations in genomes, which can be crucial for diagnosing genetic disorders and advancing research.

The American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenetic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ HemeOne laboratory-developed test (LDT) from third-party payers.

Bionano Genomics has notable partnerships and collaborations with some of the major companies in the genomics field:

Bionano Genomics has partnered with NVIDIA! They are collaborating to develop an acceleration platform for Bionano's Optical Genome Mapping (OGM) workflow. NVIDIA (NVDA) stock price = $ 140.00 a share

Revvity, Inc. (formerly PerkinElmer): This partnership focuses on newborn sequencing research and involves integrating Bionano's VIA software into Revvity's next-generation sequencing (NGS) workflow. Revvity Inc. (RVTY) stock is priced at $113.84 a share.

Bionano Genomics has partnered with Genoox! This collaboration aims to enhance the detection of disease-causing structural variants in DNA.
Genoox's platform is deployed in 44 countries and 1,700 organizations, catering to professionals in the genomic field. This widespread adoption highlights their significant impact on the global stage.

Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has partnered with Bionano Genomics.. Diagens has made significant strides in the field of in-vitro diagnostics (IVD) and AI-driven genomic analysis.

Bionano Genomics collaborates with Illumina to integrate its OGM technology with Illumina's sequencing platforms, providing a more comprehensive view of the genome and enhancing genetic analysis capabilities. Illumina Inc. (ILMN) stock is priced at $94.20 a share.

Bionano Genomics and Agilent Technologies have a collaborative relationship focused on enhancing genomic research and analysis.
Agilent's Femto Pulse system is used for quality control of genomic DNA in Bionano's Optical Genome Mapping (OGM) workflow. This system ensures that only high-quality DNA samples are used, which is crucial for the success of OGM. Agilent Technologies Inc. (A) stock is priced at $134.67 a share.

Fluctuations in stock price or questionable management decisions do not equate to a company being a scam.

AI Lied!
My source of information was AI. Now I find out the FDA NEVER approved the Saphyr System. I'll never trust AI again!

AI Lies
AI was the source of my information and now I find out that the FDA has NOT approved the Saphyr System. This is the breaking point for me and AI.

The World is Bionano Genomics (BNGO) oyster.

The FDA approval of Bionano Genomics' Saphyr system is a significant milestone that positions the company prominently on the world stage.

Here are some key impacts:

• With FDA approval, Bionano Genomics can now market and sell the Saphyr system to clinical laboratories and healthcare providers worldwide, expanding its global reach.
• FDA approval enhances the company's credibility and reputation in the genomics industry, attracting potential partners, investors, and customers.
• The approval gives Bionano Genomics a competitive edge over other companies in the genomics space that lack similar regulatory endorsements.
• The approval may lead to increased interest and investment in further research and development, driving innovation and advancements in genomic technologies.
• By providing a more comprehensive and accurate tool for detecting structural variations in the genome, the Saphyr system can improve diagnostic accuracy and patient outcomes globally.
•
Overall, the FDA approval is a significant step forward for Bionano Genomics, enhancing its global presence and potential for growth.

A Day to Celebrate BNGO – January 6, 2025

The FDA approved Bionano Genomics' Saphyr system on January 6, 2025. This approval marks a significant milestone for the company, allowing their optical genome mapping (OGM) technology to be used in clinical diagnostics.

FDA approval enhances Bionano Genomics' credibility in the genomics market. It signifies that the Saphyr system meets stringent regulatory standards for safety, efficacy, and quality. This validation gives the company a competitive edge over rivals lacking FDA approval.

With FDA approval, the Saphyr system can be marketed and sold directly to clinical laboratories and healthcare providers, rather than being limited to research-use-only applications. This opens up a larger market and potential revenue stream for Bionano Genomics.

Overall, the FDA approval of the Saphyr system is a major step forward for Bionano Genomics, positioning them as a key player in the genomics industry and paving the way for broader adoption of their innovative technology.

BNGO: What is the Fate of Bionano Genomics?

Does the Company have a future? Is it worth investing in?
Bionano Genomics is recognized as a significant player in the field of genome research, particularly for their Optical Genome Mapping (OGM) technology.
Bionano Genomics has collaborated with Agilent Technologies. Specifically, Bionano's Chinese OEM partner, Beijing Genome Precision Technology (BGPT), counts Agilent Technologies among its partners. This collaboration is part of Bionano's efforts to expand its presence and technology adoption in China.
Bionano Genomics and Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) have entered into a strategic partnership to commercialize the first-ever clinical cytogenetic analysis that combines Optical Genome Mapping (OGM) and Artificial Intelligence (AI).

Beijing Genome Precision Technology (BGPT) and Hangzhou Diagens Biotechnology Co., Ltd., are both significant players in the Chinese genomics market.. BGPT serves as Bionano Genomics' original equipment manufacturing (OEM) partner in China, focusing on distributing Bionano's reagents and instruments for in vitro diagnostics use. Diagens, on the other hand, is a local partner that has received Class II registration and approval from China's National Medical Products Administration (NMPA) for Bionano's Saphyr OGM platform.

In June 2024, BNGO and Revvity Inc., form a partnership. Revvity (BIG BUCKS) Inc,, operates a global laboratory network with state-of-the-art facilities located in strategic regions, including the United States, India, China, Sweden, and the United Kingdom. This extensive network allows Revvity to provide cutting-edge testing services and support for genetic disorders and other health conditions worldwide. Revvity's global reach enables them to serve customers across more than 190 countries, making them a major player in the health science solutions industry.

Their collaborations with these companies are significant and cover various aspects of genomic research and commercialization, particularly in reproductive health and newborn genetic testing. In short, Bionano Genomics offers tools that can lead to better health outcomes through more accurate diagnoses, improved treatments, and accessible genetic information.
The bigger question is, how can it fail? The technology is here to stay.

Revvity Inc (RVTY): You have an SOS text from BNGO

The stock price has decreased by -85.16% in the last 52 weeks.

BNGO has 101.99 million shares outstanding. The number of shares has increased by 94.65% in one year. DILUTION!!!

In the last 12 months, BNGO had revenue of $33.33 million and -$135.78 million in losses. Loss per share was -$2.21.

The last stock split was on August 7, 2023. It was a reverse split with a ratio of 10 for 1, and in 2025, the reverse split will be 60 for 1.

BNGO has a “Piotroski” F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

The latest short interest is 17.65 million, so 17.31% of the outstanding shares have been sold short.

BNGO has a market cap or net worth of $18.92 million. The enterprise value is $29.42 million.

BNGO has an “ALTMAN” Z-Score of -13.29.
(The Altman Z-Score is a formula used to predict the likelihood of a business going bankrupt within the next two years. A score below 1.8 generally suggests a high probability of bankruptcy, and a score as low as -13.29 is extremely alarming.)

BNGO has a “PIOTROSKI” F Score of 2.
(The Piotroski F-Score is a tool used to evaluate a company's financial strength based on nine criteria, with a score ranging from 0 to 92. A score of 2 means that the company only meets two of these criteria, suggesting significant financial distress and a higher risk of bankruptcy.)

Revvity has a market cap or net worth of $14.94 billion as of January 23, 2025. Its market cap has increased by 12.41% in one year.

BNGO...........................https://stockcharts.com/h-sc/ui?s=BNGO&p=W&b=5&g=0&id=p86431144783

Will China Pressure FDA’s Approval of OGM

China's National Medical Products Administration (NMPA) has approved Bionano Genomics' optical genome mapping (OGM) testing for use in hospitals. This approval allows Bionano's DNA extraction and labeling kits to be used for in vitro diagnostics (IVD) in reproductive health.

The collaboration between the two companies, which combines Bionano's OGM technology with Diagens' AI-based chromosome karyotype analysis, has been instrumental in advancing the adoption of OGM in China's healthcare system.

Diagens believes that combining Bionano's optical genome mapping (OGM) technology with their AI chromosome karyotype analysis can significantly improve the success rate of in vitro fertilization (IVF) and potentially expand into other fields like blood cancer in the future.

International approvals can positively influence the FDA's decision-making process.

Happy New OGM Code 2025!

Category I CPT Code for Bionano Genomics. The code, which went into effect on January 1, 2025, is for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies.

This approval is significant as it implies acceptance by the medical community and is expected to help with reimbursement for the OGM-Dx™ HemeOne laboratory developed test (LDT) from third-party payers (insurance companies).

The HemeOne laboratory developed test (LDT) is a special test created by Bionano Laboratories to help diagnose and manage blood cancers (hematological malignancies) like leukemia and lymphoma.

The test uses a technique called optical genome mapping (OGM) to look for changes in the DNA that might indicate the presence of these cancers. The test can detect structural variants (SVs) in the DNA that are important for understanding the specific type and characteristics of the lymphoma.

By identifying specific genetic changes, oncologists can tailor treatment plans to target those changes more effectively. This can lead to better outcomes and more personalized care. The test can be used to monitor the patient's response to treatment and detect any potential relapses or changes in the disease over time.

The partnership between Revvity and Bionano Genomics strengthens their position in the genomic testing market, especially for applications requiring detailed genomic analysis. Revvity's substantial resources and expertise in sequencing, paired with Bionano's innovative Stratys system for optical genome mapping (OGM), create a powerful synergy.

RVTY + BNGO + MIT = Best & Brightest in Science


Revvity and Bionano Genomics entered into an agreement in June 2024, for Revvity to use Bionano’s VIA Software in their sequencing.

Revvity has a relationship with the Massachusetts Institute of Technology (MIT). MIT's Information Systems & Technology (IS&T) department licenses several of Revvity's products, such as ChemOffice+ Cloud and ChemDraw, for use by the MIT community. Additionally, Revvity collaborates with MIT on various initiatives, including career advising and professional development opportunities.

At MIT, ChemOffice and ChemDraw are widely used by faculty, staff, and students for academic and research purposes. MIT's Information Systems & Technology (IS&T) department provides licenses for these products to the MIT community, ensuring that everyone has access to these powerful tools.

Someone said, guys like Elon Musk and MIT are engaged in technology that is years ahead of the common man. This is a trinity of geniuses in science that is unsurpassed.

You can buy into this trinity as it goes forth and revolutionizes the study of genomics among other discoveries. Revvity’s stock symbol is RVTY and goes for $151.00 a share or Bionano Genomics their symbol is BNGO and the stock can be bought for $0.27 cents a share.

Look for .55-.67 zone in future then
Revisit 

.34 + 20%

bngo....................................https://stockcharts.com/h-sc/ui?s=bngo&p=W&b=5&g=0&id=p86431144783

.41

Ready here phenomenal studies
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor AnalysisDecember 23 2024 - 8:30AM

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors.Key findings:OGM detected all variants revealed by conventional cytogenetics: OGM showed 100% concordance, identifying all pathogenic variants detected by standard of care cytogenetic methods. The specificity of OGM was assessed to be 100%, i.e. OGM correctly identified the same pathogenic SVs and CNVs detected by standard of care/routine cytogenetics (karyotyping and FISH).OGM detected pathogenic variants missed by karyotyping: In 74% of cases with normal or failed karyotype, OGM detected diagnostic or pathogenic SVs that were missed by karyotyping. Further, in 6 cases that failed to yield any karyotyping results due to culture failure, OGM detected pathogenic SVs in all of them. Variants found by OGM but missed by standard of care included the EWSR1::ETV1 fusion, which is a key molecular hallmark of clear cell sarcoma and helps to differentiate it from other soft tissue sarcomas and melanomas.OGM resolved complex cancer genomes: Study authors found that OGM data could re-characterized and better defined complex structural rearrangements including chromoanagenesis in 27% of cases and complex 3-6-way translocations in 15% of cases when compared to traditional cytogenetic methods.OGM combined with NGS found pathogenic variants in 98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used: The integrated approach of the combination of OGM and NGS resulted in the detection of pathogenic SVs and sequence variants in ~98% of cases. OGM was 100% concordant with NGS for aneuploidy detection.OGM findings have the potential to qualify subjects for targeted therapies that otherwise would not have been possible: The authors state that several of the OGM findings could result in the potential for these cases to qualify for either targeted treatments or clinical trials. For example, cases with potential to be treated by CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), TRK inhibitors (larotrectinib, entrectinib), pan-FGFR inhibitors (erdafitinib or futibatinib) were highlighted.
Erik Holmlin, president and chief executive officer of Bionano commented, “Approximately 50% of bone and soft tissue tumor samples fail to reveal actionable information for proper classification of disease, prognosis and therapeutic management because they either fail to culture or because traditional techniques in cytogenetics lack adequate sensitivity and specificity to reliably detect relevant variants. We have seen increasing evidence for OGM as a valuable alternative to cytogenetic methods in blood cancers, and we are thrilled to see researchers at Johns Hopkins publishing this compelling case for extending OGM’s utility to bone and soft tissue tumors.”The full research publication is available at:https://doi.org/10.1016/j.modpat.2024.100684

.40

That's how it's done bear it down merciless first 

Bingo .37 

BNGO..........................................................a/h

The truth will set you free

I really think I have something here, ever since I started posting about the possibility of Revvity buying out BNGO I have been banned on Wallstreetbets, roaringkitty, and pennystocks, to name a few. I was okay talking about the technology, but when I brought up Revvity's deep pockets and buying BioLegend for 5 BILLION and the fact they could buy BNGO with petty cash, I got shut out.

I think Revvity buying BNGO is a very real possibility. For some reason, and don't take my word for it, nobody is talking about Revvity, its just the sound of crickets. Here is my prediction, BNGO is going to initiate a BIG reverse split and when the dust settles Revvity will buy out Bionano Genomics for around 250 to 500 million.

Remember, they bought BioLegend for 5 BILLION, so millions are nothing to them. The sad truth is they will get the Stratys System, which is a much better deal than BioLegend and for pennies.

I believe this was a sneaky contrived plot on the part of BNGO management. Call me a conspiracy theorist, but the technology is phenomenal, and they can’t pull it together financially?

Another point, what analyst have you heard talk about Revvity and BNGO teaming-up and creating a better product than the individual companies of Illumina, Thermo Fisher, and Agilent. It is being initiated worldwide by Revvity! There go the crickets, Chirp! Chirp!

Holy Trinity of Genomics Research

Dateline, June 20, 2024, Bionano Genomics and Revvity Inc., announce their partnership.
Revvity completed its acquisition of BioLegend on September 17, 2021.

Revvity, BioLegend, and Bionano Genomics offer a more integrated approach by combining diagnostics, antibodies, and genome mapping technologies. This can provide a more complete picture of genetic and cellular data.

Bionano Genomics' OGM technology offers detailed DNA imaging, which can complement Revvity's sequencing tools and BioLegend's reagents, leading to more accurate and comprehensive research outcomes.

The collaboration between these three companies can lead to better diagnostic tools and treatments, especially in areas like newborn sequencing and rare disease research.

In essence, the trinity of Revvity, BioLegend, and Bionano Genomics offers a more integrated and advanced approach to genomics research compared to the individual strengths of Thermo Fisher, Agilent, and Illumina.

BNGO is standing on Third Base

…it is Soooo close to crossing home plate and becoming the Standard Bearer of Genomics.

Bionano Genomics suite of products: Stratys System, Via Software, EnFocus Analysis, Hematological Malignancy Workflow, Variant Intelligence Applications, Bionano Access, and Bionano Solve, significantly improve discovering key chromosomal aberrations
excluded by current methods.

I predict history will repeat itself: Dateline, February 16, 2021, BNGO share price $155,70. This was driven by optimism about their genome analysis technology and POTENTIAL partnerships.

Dateline, June 20, 2024, Bionano Genomics and Revvity Inc., announce their partnership. This partnership is REAL and significant union. The agreement will see Bionano’s state-of-the-art software integrated into Revvity’s already robust newborn sequencing research workflow.

Significance of partnership: Revvity, Inc.(formerly known as PerkinElmer) has a market capitalization of approximately $14.11 billion (BILLION) Stock Symbol “RVTY” $109.14 (12.19.2024) share price.

Once a certain standard of technology is achieved, it sets a new benchmark that propels forward, never backward. This principle is aptly reflected in Bionano Genomics’ Stratys System and VIA Software.

Revvity recognized the potential and value of Binano Genomics’ OGM technology and has a vested interest in ensuring its continued success. Revvity did not enter into this partnership without due-diligence. Revvity fully realizes the cutting-edge technology that could redefine industry standards.

It’s a classic case of technological evolution where once a new peak is reached, the journey ahead focuses on exploring new heights and possibilities.

Revvity, Inc…BNGO…Partnership…Takeover?

Revvity, Inc.(formerly known as PerkinElmer) has a market capitalization of approximately $14.11 billion (BILLION) Stock Symbol “RVTY” $109.14 (12.19.2024) share price

Revvity's partnership with Bionano Genomics is quite extensive and strategic. Announced on June 20, 2024, the partnership focuses on newborn sequencing research and involves the integration of Bionano's VIA software into Revvity's next-generation sequencing (NGS) workflow. The agreement will see Bionano’s state-of-the-art software integrated into Revvity’s already robust newborn sequencing research workflow.

Bionano Genomics will NEVER, NEVER-EVER, go bankrupt. Revvity would buy BNGO for their Stratys System & OGM. Revvity would take the money from their petty cash drawer.

The collaboration between Bionano Genomics and Revvity could STRENGTHEN BNGO’s appeal with the FDA. Revvity has EXTENSIVE experience and MARKET PRESENCE in the clinical and research fields.

This increased usage and validation in clinical settings could support Bionano's case for FDA approval.

Will Revvity eventually take over Bionano Genomics ????

Should I Stay or Should I Go
The Clash (stockholders vs Board)

Erik, Darling, you got to let me know
Should I stay or should I go?
If you say that we are fine
I'll be here 'til the end of time

So you got to let me know
Should I stay or should I go?
It’s always dilute, dilute, dilute
And you seem happy when I lose

One day is fine and next it’s Cracked
So if you want me off your back
Be straight with me, quit talking smack

If I stay will BNGO double
Or will you let OGM turn to rubble

Do WE Vote YES, NO, or ABSTAIN

BNGO did a reverse split of 1 for 10 in August 2023. Since then, Erik Holmlin
Increased (diluted) BNGO shares by 89 MILLION, raising money for the Company.

A number of shareholders highlight the fact the Company is in dire straits, however Erik
never took a pay cut to help out.

BNGO will hold a shareholders meeting on January 15,2025. On the agenda are the following:
A reverse split for either 1 for 25 or 1 for 75, and increasing (diluting) overall share by 19 million.

My question is, and I am looking for advice: Do we vote YES, NO, or ABSTAIN?
So, if you how have 25,000 shares of BNGO, and the reverse comes, you will
either have 1,000 shares or 333 shares.

Comments, Please!

Investors & Advocates For Approval of OGM

There’s a new sheriff is in town: Robert F. Kennedy Jr. Robert F. Kennedy Jr. has been quite vocal about his plans to overhaul the FDA.
When researchers, clinicians, and investors come together to advocate for a promising technology, it can bring attention to its potential benefits and the urgency of its approval.
Public pressure, combined with robust research and evidence (Worldwide acceptance), can expedite the regulatory process. It's important to continue raising awareness and ensuring that the voices of those who support OGM are heard.

Here's a draft of an open letter you can use to advocate for the approval of Bionano Genomics' Optical Genome Mapping (OGM):
[Your Name] [Your Address] [City, State, ZIP Code] [Email Address] [Date]

Dr. Jeffrey Shuren
Director, Center for Devices and Radiological Health Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-000

Dear Dr. Shuren,

I am writing to express my strong support for the approval of Bionano Genomics' Optical Genome Mapping (OGM) technology. As a [researcher/investor/clinician/advocate], I believe that OGM has the potential to revolutionize genomic analysis and diagnostics, providing significant benefits to patients and the healthcare community.

The acceptance of OGM by prestigious institutions such as the Mayo Clinic and Johns Hopkins underscores its credibility and potential. Furthermore, extensive testing and research conducted worldwide have demonstrated the efficacy and safety of this technology. However, despite these promising developments, the approval process for OGM appears to be facing unnecessary delays.

I urge the FDA, specifically the Office of Health Technology 7 (OHT7), to prioritize the evaluation and approval of OGM. The timely approval of this technology is crucial for advancing genomic research and improving patient outcomes.

Thank you for your attention to this matter. I look forward to a positive resolution and the continued advancement of genomic science.
Sincerely, [Your Name]

(lets start a ground swell of getting the FDA to approve OGM)

BNGO, new 52;week low

BNGO...29...No Position...🥳...just watching to see where she lands following this offering...SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the “Warrants”) at a combined offering price of $0.3039 per share of common stock and accompanying Warrants, in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”). The Series C warrants will expire five years following the date of the Stockholder Approval and the short-term Series D warrants will expire eighteen months following the date of Stockholder Approval. The closing of the offering is expected to occur on or about October 31, 2024, subject to the satisfaction of customary closing conditions.

Hi Vacationhouse. It’s been a while. Look for me on CAPR. Finally making up for my WAVX losses

LMAO. Think of it as a lottery ticket. Your most likely going to lose your money, but you might not.

Is it stabilized now? Almost.... Imma buy 20 bucks worth just for my radar.

At least the executives get nice bonuses, with the recent layoff of ~120 employees

BNGO new 52 lo

BNGO under $2

BNGO 10Q due March 5

BNGO under $2

BNGO new 52 week low

BNGO new 52 week low

BNGO will.be extremely valuble when the new pandemic pathogen shows up at our borders.....the whole world needs this technology...they just don't realize it ....yet

Today it's @ $ 1.18. I think it is time for another Reverse Split, that will attract new investors. It didn't work the last time, but why not? My logic is if they keep reverse-splitting, I will be able to buy 1 million shares for 10 bucks at some point. $0.0001

Reverse Stock Split

The downside of a reverse stock split is that it can be perceived as a negative signal by investors. It made me put a hold on any further buys. A reverse split can also lead to a decrease in liquidity and trading volume, which makes it more difficult for investors to buy and sell shares.

Why is this still diving? We have shown profitability and cost cutting?
https://finance.yahoo.com/news/bionano-genomics-inc-bngo-reports-231922361.html

BNGO under $2

1.20 new low. Divergence starting to tighten up a bit more. Needs the volume and find a solid bottom. Getting closer imo.

BNGO new 52 week low

BNGO new 52 week low

I was just looking at this. Since it looks to be getting the crap kicked out of it. $1.30's, $80M offering (WOW!) and to see what else is happening. Benn a while since I was in this one.

Looks like it's starting to set up. Ned to see bottom confirmation.

I misspoke, it isn't to save the day, it is saving our butts.

ALERT * Institutional Investors * ALERT

BNGO Management did a Reverse-Split to attract you as an investor and now the Stock is down to $ 1.62.
I think it is high time you guys came in and saved the day for us long-term investors. THANK YOU!